MLYS — Mineralys Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1933414 ·
Last close
$23.37
Market Cap
$2.07B
52W High
$47.65
52W Low
$21.46
ADV30
1,422,650
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -246,040,000 | -241,071,000 | 667,853,000 | 138,268,000 | 116,936,000 |
| Mar 2026 | 0 | — | -45,340,000 | -39,339,000 | 652,862,000 | 112,779,000 | 14,718,000 |
| Dec 2025 | 0 | — | -38,280,000 | -32,234,000 | 661,806,000 | 172,921,000 | 15,113,000 |
| Sep 2025 | 0 | — | -41,131,000 | -36,932,000 | 599,947,000 | 217,597,000 | 23,520,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-136,400,000
Investing CF
$-341,820,000
Financing CF
$425,992,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.05
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-496,508,000
Inventory
—
Receivables
—
ST Investments
$533,281,000
EBIT TTM
$-171,497,000
Pretax Income TTM
$-151,779,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -170,604,000 | -154,651,000 | 661,806,000 | 15,113,000 | 646,693,000 | -142,416,000 |
| Dec 2024 | 0 | -192,403,000 | -177,810,000 | 205,903,000 | 14,646,000 | 191,257,000 | -166,314,000 |
| Dec 2023 | 0 | -84,657,000 | -71,898,000 | 251,636,000 | 10,482,000 | 241,154,000 | -81,173,000 |
| Dec 2022 | 0 | -31,479,000 | -29,799,000 | 114,442,000 | 166,711,000 | -52,269,000 | -29,221,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-151,779,000
OpCashFlow TTM
—
Assets (Latest)
$652,862,000
Forward EPS
$-2.50
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRGO | PERRIGO Co plc | $2.08B | $15.06 | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $2.11B | $18.66 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $2.00B | $138.77 | — |
| VERA | Vera Therapeutics, Inc. | $2.15B | $29.88 | — |
| PHVS | Pharvaris N.V. | $2.18B | $31.10 | — |
News headlines (Yahoo Finance, 1h cache)
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
2026-10-09 13:00 · Yahoo
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-09-29 20:05 · Yahoo
Mineralys Therapeutics (MLYS) Faces A Fresh Valuation Test On New Lorundrostat Data
2026-09-28 17:08 · Yahoo
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
2026-09-24 20:05 · Yahoo
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
2026-09-23 20:05 · Yahoo
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
2026-08-26 12:00 · Yahoo
Mineralys (MLYS) Q2 2026 Earnings Call Transcript
2026-08-18 23:13 · Yahoo
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2026-08-13 20:05 · Yahoo
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...
2026-08-12 05:01 · Yahoo
Mineralys Therapeutics Q2 Earnings Call Highlights
2026-08-11 23:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.